MGN1703: Interim Phase II data

Mologen reported that an initial assessment of data from 55 evaluable patients with mCRC in the double-blind, international Phase II IMPACT trial showed that twice-weekly 60 mg MGN1703 as maintenance therapy met the primary endpoint of median PFS vs. placebo. Specifically, median PFS in an undisclosed pre-defined target population of 46 patients showed that MGN1703 more than doubled median PFS vs. placebo (p<0.02). MGN1703 also met the secondary endpoint of a greater PFS rate after 6 months vs. placebo. MGN1703 was well tolerated. Based on the data, Mologen prematurely stopped enrollment in the trial at 58 patients. OS data will continue to be collected. The trial had planned to enroll 129 patients who had disease stabilization or partial or complete remission of their cancer after receiving first-line therapy with chemotherapy plus Avastin bevacizumab for 4.5-6 months. ...